Pooled analysis of 12 randomized trials suggests use of concurrent\/adjuvant androgen deprivation therapy in combination with prostate-only radiotherapy may improve outcomes<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Oct. 31, 2022 (HealthDay News) — When short-term androgen-deprivation therapy (ADT) is indicated in combination with prostate-only radiotherapy (PORT) for localized prostate cancer, concurrent\/adjuvant ADT may result in better outcomes, according to a study published online Oct. 21 in the Journal of Clinical Oncology<\/em>.<\/p>\n Ting Martin Ma, M.D., Ph.D., from the University of California in Los Angeles, and colleagues examined the impact of ADT sequencing for men receiving ADT with PORT or whole-pelvis RT (WPRT). Individual patient data were included from 12 randomized trials with patients receiving neoadjuvant\/concurrent or concurrent\/adjuvant short-term ADT (four to six months) with RT for localized disease (6,325 and 1,084 men, respectively). Metastasis-free survival and overall survival were assessed by inverse probability of treatment weighted-adjusted Cox regression models analyzed for men receiving PORT versus WPRT.<\/p>\n The researchers found that for all end points except overall survival, there was a significant interaction observed between ADT sequencing and RT field size. With PORT, concurrent\/adjuvant ADT was associated with improved metastasis-free survival (hazard ratio, 0.65), distant metastasis (subdistribution hazard ratio, 0.52), prostate cancer-specific mortality (subdistribution hazard ratio, 0.30), and overall survival (hazard ratio, 0.69) versus neoadjuvant\/concurrent ADT. For patients receiving WPRT, there was no significant difference observed in any end point, apart from worse distant metastasis with concurrent\/adjuvant ADT (hazard ratio, 1.57).<\/p>\n “To our knowledge, this study represents the first time a significant association has been demonstrated between concurrent and adjuvant ADT sequencing and overall survival rates among prostate cancer patients,” a coauthor said in a statement. “For patients receiving prostate-only RT, concurrent\/adjuvant sequencing is associated with optimal outcomes.”<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n